Glioma Treatment Market to Grow to $6.4 Billion by 2028 Driven by Rise in Brain and CNS Tumor Incidence

The glioma treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.03 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to risen incidence of gliomas, advancements in molecular understanding, evolution of standard therapies, clinical trials and research progress, improved imaging and diagnostic techniques.

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized therapies and biomarker discovery, immunotherapeutic advancements, integration of targeted therapies, emergence of novel therapeutic platforms, collaborative research initiatives. Major trends in the forecast period include blood-brain barrier penetrating agents, liquid biopsy for monitoring, focus on quality of life and supportive care, genetic and molecular subtyping, patient advocacy and involvement.

Market Overview -
Glioma treatment refers to a treatment that reduces symptoms, removes and control the tumor and limits long-term damage to the brain or spinal cord. They are used to kills any glioma cells that might remain after surgery.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10689&type=smp

Glioma Treatment Market Driven By The Surge In Brain And Cns Tumor Incidence
The rise in brain and CNS tumor incidence is expected to propel the growth of the glioma treatment market going forward. Brain and spinal cord tumors are uncontrolled masses of abnormal brain or central nervous systems. Glioma treatment is used in brain and spinal cord cancer to destroy any remaining cancer cells or parts of the tumor after surgery. For instance, in August 2021, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, it is estimated that 24,530 malignant tumors and 59,040 nonmalignant tumors will be identified with brain and other CNS cancers in the United States in 2021, accounting for 83,570 cases, and 18,600 deaths from the disease. Therefore, the rise in the incidence of brain and spinal cord tumors is driving the growth of the glioma treatment market.

Competitive Landscape -
Major companies operating in the glioma treatment market report are Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

Daiichi Sankyo Introduces Innovative Glioma Treatment With Launch Of The World's First Oncolytic Virus Therapy For Brain Cancer
Product innovation is a key trend gaining popularity in the glioma treatment market. Major companies operating in the glioma treatment market are adopting new innovative products to sustain their position in the market. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, launched Delytact, a cancer-fighting virus and the world's first oncolytic virus therapy for brain cancer. Its viral genome carries three triple mutations that enhance and selectively replicate in cancer cells and aid in treating malignant glioma.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Key Segments -
The glioma treatment market covered in this report is segmented -
1) By Type: Low-Grade, High-Grade
2) By Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Drug Therapy, Other Treatments
5) By End-User: Hospitals, Specialty Clinics, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.